Sign in
EFTR Stock Price, Chart, Stats & News
eFFECTOR Therapeutics, Inc.
Save
eFFECTOR Therapeutics, Inc. (EFTR) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
EFTR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -174.31% |
ROE | 3771.56% |
D/E | -3.55x |
Interest coverage ratio | – |
EFTR valuation
P/E | – |
P/S | – |
P/B | -0.00x |
P/CF | -0.00x |
P/FCF | -0.00x |
P/OCF | -0.00x |
PEG | -0.00x |
EV multiple | 0.17x |
About
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer.
Similar securities
Based on sector and market capitalization
Report issue